Epidemic Intelligence Service, Division of Applied Sciences, Scientific Education and Professional Development Program Office.
Infect Drug Resist. 2011;4:161-9. doi: 10.2147/IDR.S21545. Epub 2011 Sep 21.
Meningococcal conjugate vaccines have several advantages over polysaccharide vaccines, including the ability to induce greater antibody persistence, avidity, immunologic memory, and herd immunity. Since 1999, meningococcal conjugate vaccine programs have been established across the globe. Many of these vaccination programs have resulted in significant decline in meningococcal disease in several countries. Recent introduction of serogroup A conjugate vaccine in Africa offers the potential to eliminate meningococcal disease as a public health problem in Africa. However, the duration of immune response and the development of widespread herd immunity in the population remain important questions for meningococcal vaccine programs. Because of the unique epidemiology of meningococcal disease around the world, the optimal vaccination strategy for long-term disease prevention will vary by country.
脑膜炎球菌结合疫苗相对于多糖疫苗具有多种优势，包括诱导更强的抗体持久性、亲和力、免疫记忆和群体免疫的能力。自 1999 年以来，脑膜炎球菌结合疫苗项目已在全球范围内建立。其中许多疫苗接种项目已导致一些国家的脑膜炎球菌病显著下降。最近在非洲推出的 A 群脑膜炎球菌结合疫苗有可能消除非洲脑膜炎球菌病这一公共卫生问题。然而，免疫反应的持续时间以及人群中广泛的群体免疫力的发展仍然是脑膜炎球菌疫苗项目的重要问题。由于世界各地脑膜炎球菌病的独特流行病学，长期预防疾病的最佳疫苗接种策略因国家而异。
